Source comparison
BPC-157 Plantar Fasciitis Mechanism: Protocol Comparison
BPC-157 subcutaneous injection (250–500mcg daily) Growth factor receptor activation + FAK signaling + collagen synthesis 6–10 weeks for structural repair; pain reduction may occur earlier (weeks 3–5) High. Promotes organized Type I collagen deposition and neov
This comparison does not assign a generated winner or score.
- BPC-157 subcutaneous injection (250–500mcg daily)
- Growth factor receptor activation + FAK signaling + collagen synthesis
- 6–10 weeks for structural repair; pain reduction may occur earlier (weeks 3–5)
- High. Promotes organized Type I collagen deposition and neovascularization
- Best option for chronic fasciitis with structural damage; requires consistent administration and realistic timeline expectations
- Oral BPC-157 (stable salt forms, 500–1000mcg daily)
- Same molecular pathways but systemically distributed rather than locally concentrated
- 8–12 weeks; slower onset due to lower bioavailability at injury site
- Moderate. Less localized concentration means slower tissue remodeling
- Viable alternative for users avoiding injections; requires higher dosing and longer timeline
- PRP (platelet-rich plasma) injection
- Delivers autologous growth factors (PDGF, TGF-β, IGF-1) to stimulate healing
- Single injection; effects visible at 6–8 weeks
- High. Proven collagen synthesis and pain reduction in clinical trials
- Effective but requires clinical administration; one-time cost ($500–$1200) vs ongoing peptide protocol
- Corticosteroid injection
- Anti-inflammatory; suppresses pain signaling but does NOT promote collagen synthesis
- Immediate pain relief (24–72 hours); lasts 4–12 weeks
- Low. May weaken fascia tissue with repeated use; no structural repair
- Symptom management only; does not address underlying collagen degeneration and may delay healing